- Johnson & Johnson will invest $2 billion over 10 years to establish a 160,000+ sq ft manufacturing facility at FUJIFILM Biotechnologies’ Holly Springs site in North Carolina, creating around 120 new jobs.
- The Company plans additional U.S. advanced manufacturing facilities and expansions to existing sites, supporting its domestic production of advanced medicines.
Johnson & Johnson has announced plans to expand its U.S. manufacturing footprint with a 160,000+ square foot facility at Fujifilm‘s biopharmaceutical manufacturing site in Holly Springs, North Carolina. The $2 billion investment over the next decade is expected to create approximately 120 new jobs in the state.
The investment forms part of the J&J’s broader strategy to enhance its domestic production of advanced medicines. Future plans include additional manufacturing facilities and expansions at current U.S. sites. According to the press release, these developments will support the manufacture of the majority of Johnson & Johnson’s advanced medicines for U.S. patients.
“Johnson & Johnson has more manufacturing facilities in the U.S. than in any other country, and we continue to strengthen our presence here,” said Joaquin Duato, Chairman and CEO. He added that recent legislation, including the One Big Beautiful Bill Act, will further support the Company’s U.S. expansion.
This expansion aligns with Johnson & Johnson’s $55 billion U.S. investment plan announced in March, aimed at supporting manufacturing, research and development, and technological advancements over the next four years. The Holly Springs site is expected to enhance Johnson & Johnson’s capacity to manufacture advanced medicines domestically and support thousands of jobs nationwide.
By leveraging FUJIFILM Biotechnologies’ state-of-the-art facility, Johnson & Johnson aims to reinforce its domestic production capabilities, ensuring the majority of its advanced medicines can be produced in the U.S. to meet patient needs.
The deal follows Fujifilm’s $3+ billion Regeneron deal earlier this year, further positioning the CDMO as a major force in US contract manufacturing.
Last month we sat down with Toshihisa Iida, Chairman of FUJIFILM Biotechnologies to talk about his growth strategy on the PharmaSource podcast.
He explained that “Current revenue is $1.3 billion. We anticipate it will grow to $5 billion in five years’ time. We’ve committed to invest about two-thirds of Fujifilm’s entire annual capex in this business.”
Listen to the episode to hear Toshi unpack their strategy, including the innovative “kojoX” approach that he describes as “the industry’s largest interconnected, modular network of bio-manufacturing facilities.”
